These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35587448)

  • 21. Successful treatment of congenital hyperinsulinism with long-acting release octreotide.
    Le Quan Sang KH; Arnoux JB; Mamoune A; Saint-Martin C; Bellanné-Chantelot C; Valayannopoulos V; Brassier A; Kayirangwa H; Barbier V; Broissand C; Fabreguettes JR; Charron B; Thalabard JC; de Lonlay P
    Eur J Endocrinol; 2012 Feb; 166(2):333-9. PubMed ID: 22048969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of Adverse Events in Children With Congenital Hyperinsulinism Treated With Diazoxide.
    Herrera A; Vajravelu ME; Givler S; Mitteer L; Avitabile CM; Lord K; De León DD
    J Clin Endocrinol Metab; 2018 Dec; 103(12):4365-4372. PubMed ID: 30247666
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The hyperinsulinism/hyperammonemia syndrome.
    Palladino AA; Stanley CA
    Rev Endocr Metab Disord; 2010 Sep; 11(3):171-8. PubMed ID: 20936362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein-sensitive hypoglycemia without leucine sensitivity in hyperinsulinism caused by K(ATP) channel mutations.
    Fourtner SH; Stanley CA; Kelly A
    J Pediatr; 2006 Jul; 149(1):47-52. PubMed ID: 16860127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A dose-finding study of lanreotide (a somatostatin analog) in patients with colorectal carcinoma.
    Di Leo A; Bajetta E; Ferrari L; Biganzoli L; Mariani L; Carnaghi C; Camerini E; Buzzoni R; Ruiz JM
    Cancer; 1996 Jul; 78(1):35-42. PubMed ID: 8646723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genotype and phenotype correlations in 417 children with congenital hyperinsulinism.
    Snider KE; Becker S; Boyajian L; Shyng SL; MacMullen C; Hughes N; Ganapathy K; Bhatti T; Stanley CA; Ganguly A
    J Clin Endocrinol Metab; 2013 Feb; 98(2):E355-63. PubMed ID: 23275527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical characteristics and biochemical mechanisms of congenital hyperinsulinism associated with dominant KATP channel mutations.
    Pinney SE; MacMullen C; Becker S; Lin YW; Hanna C; Thornton P; Ganguly A; Shyng SL; Stanley CA
    J Clin Invest; 2008 Aug; 118(8):2877-86. PubMed ID: 18596924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide.
    Caron P; Morange-Ramos I; Cogne M; Jaquet P
    J Clin Endocrinol Metab; 1997 Jan; 82(1):18-22. PubMed ID: 8989225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucose status in patients with acromegaly receiving primary treatment with the somatostatin analog lanreotide.
    Couture E; Bongard V; Maiza JC; Bennet A; Caron P
    Pituitary; 2012 Dec; 15(4):518-25. PubMed ID: 22058008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly.
    al-Maskari M; Gebbie J; Kendall-Taylor P
    Clin Endocrinol (Oxf); 1996 Oct; 45(4):415-21. PubMed ID: 8959079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.
    Capdevila J; Sevilla I; Alonso V; Antón Aparicio L; Jiménez Fonseca P; Grande E; Reina JJ; Manzano JL; Alonso Lájara JD; Barriuso J; Castellano D; Medina J; López C; Segura Á; Carrera S; Crespo G; Fuster J; Munarriz J; García Alfonso P
    BMC Cancer; 2015 Jul; 15():495. PubMed ID: 26138480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Marked alteration of glycemic profile surrounding lanreotide administration in acromegaly: A case report.
    Tanaka S; Haketa A; Yamamuro S; Suzuki T; Kobayashi H; Hatanaka Y; Ueno T; Fukuda N; Abe M; Yoshino A; Soma M
    J Diabetes Investig; 2018 Jan; 9(1):223-225. PubMed ID: 28390105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.
    Michael M; Garcia-Carbonero R; Weber MM; Lombard-Bohas C; Toumpanakis C; Hicks RJ
    Oncologist; 2017 Mar; 22(3):272-285. PubMed ID: 28220021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly.
    Kendall-Taylor P; Miller M; Gebbie J; Turner S; al-Maskari M
    Pituitary; 2000 Oct; 3(2):61-5. PubMed ID: 11141697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
    Fisher GA; Wolin EM; Liyanage N; Lowenthal SP; Mirakhur B; Pommier RF; Shaheen M; Vinik AI;
    Endocr Pract; 2018 Mar; 24(3):243-255. PubMed ID: 29547049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects.
    Eriksson B; Renstrup J; Imam H; Oberg K
    Ann Oncol; 1997 Oct; 8(10):1041-4. PubMed ID: 9402179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Congenital hyperinsulinism: current trends in diagnosis and therapy.
    Arnoux JB; Verkarre V; Saint-Martin C; Montravers F; Brassier A; Valayannopoulos V; Brunelle F; Fournet JC; Robert JJ; Aigrain Y; Bellanné-Chantelot C; de Lonlay P
    Orphanet J Rare Dis; 2011 Oct; 6():63. PubMed ID: 21967988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide.
    Kuhn JM; Arlot S; Lefebvre H; Caron P; Cortet-Rudelli C; Archambaud F; Chanson P; Tabarin A; Goth MI; Blumberg J; Catus F; Ispas S; Beck-Peccoz P
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1487-91. PubMed ID: 10770186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients.
    Berruti A; Dogliotti L; Mosca A; Tarabuzzi R; Torta M; Mari M; Gorzegno G; Fontana D; Angeli A
    Prostate; 2001 May; 47(3):205-11. PubMed ID: 11351350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differing effects on gall-bladder motility of lanreotide SR and octreotide LAR for treatment of acromegaly.
    Turner HE; Lindsell DR; Vadivale A; Thillainayagam AV; Wass JA
    Eur J Endocrinol; 1999 Dec; 141(6):590-4. PubMed ID: 10601961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.